Drug Discovery News talked with Paul Grayson, Bird Rock Bio’s president and CEO, about development of therapeutic antibody namacizumab and their recent deal with Janssen Pharmaceuticals and GE Healthcare.
Namacizumab is unique in that antibody that stabilizes the cannabinoid 1 (CB1) receptor in an inactive conformation. Increases in CB1 activity have been indicated in progression of fibrotic and metabolic liver diseases. Namacizumab is being developed to target this increased activity and treat large unmet medical needs in diseases such as non-alcoholic steatohepatitis (NASH) and diabetic nephropathy.
Under the recent agreement, Janssen received an exclusive option to acquire Bird Rock following a Phase 1 data readout. Furthermore, GE Healthcare has agreed to partner with Bird Rock for process development, formulation, and manufacturing of namacizumab in preparation for Phase 2 studies.
Read the full story at Drug Discovery News.
More details on the partnerships and namacizumab in our recent press release.